ther 18 countries in 2014, and is approved in approximately 50 countries worldwide. Marketing authorization applications are under review in various other countries. The main countries contributing to sales of Zaltrap in 2015 were the U.S., Germany, France, Spain, Italy, and the U.K. Established Prescription Products and Other Products Plavix/Iscover Plavix (clopidogrel bisulfate), a platelet adenosine diphosphate (ADP) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by ADP, is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent ischemic stroke or established peripheral arterial disease. Plavix is indicated for patients with acute coronary syndrome (ACS): For patients with non-ST-segment elevation ACS, including unstable angina/nonQ-wave myocardial infarction (MI), including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or coronary artery bypass grafting, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke, as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia; For patients with ST-segment elevation acute myocardial infarction, Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. Plavix is also indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic and thromboembolic events in Atrial Fibrillation, including stroke. CoPlavix/DuoPlavin, a fixed-dose combination of clopidogrel bisulfate and ASA, is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome who are already taking both clopidogrel and ASA. Generics were launched in Japan starting in June 2015 (for stroke indication), October 2015 (for MI) and are expected to be launched in the fourth quarter of 2016 for the PAD indication. Plavix is the leading anti-platelet in the Chinese market. The main countries contributing to sales of Plavix/Iscover in 2015 were Japan and China. Lovenox/Clexane Lovenox (enoxaparin sodium) has been used to treat approximately 500 million patients in approximately 100 countries since its launch and is registered for a range of clinical indications than any other low molecular weight heparin (LMWH). Its clinical dossier has demonstrated a favorable risk-benefit ratio, including in the prophylaxis and treatment of venous thromboembolism and in the treatment of acute coronary syndrome. In the prevention of venous thromboembolism, the use of Lovenox continues to grow, particularly in the area of prophylaxis of deep vein thrombosis (DVT) in patients hospitalized for an acute medical condition. In the U.S., three enoxaparin generics have been approved, as well as the company’s own Lovenox generic. No biosimilar of Lovenox has been authorized in the E.U. yet. In 2015, Lovenox was the major injectable anti-thrombotic in all European countries. Aprovel/Avapro/Karvea Aprovel (irbesartan) is an anti-hypertensive belonging to the class of angiotensin II receptor antagonists. These antagonists act by blocking the effect of angiotensin II, the hormone responsible for blood vessel contraction, thereby enabling blood pressure to return to normal. In addition to Aprovel/Avapro/Karvea, the company also markets CoAprovel/Avalide/Karvezide, a fixed-dose combination of irbesartan and hydrochlorothiazide (HCTZ), a diuretic that increases the excretion of water and sodium by the kidneys and provides an additional blood pressure lowering effect. These products achieve control of blood pressure in approximately 80% of patients, with a good safety profile. Aprovel and CoAprovel tablets are available in a range of dosages to fit the needs of patients with different levels of hypertension severity. Aprovel is indicated as a first-line treatment for hypertension and for the treatment of nephropathy in hypertensive patients with type 2 diabete
sanofi-titr part10%87 (RHPP:EN Paris)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for RHPP.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.